BioNano Genomics - breakout - possible Q1/Q2 mitd-term route
CRISPR - Bullish - mid-term - Q1/Q2 possible route
After a bit of correction and going down to sub $9 last week, buy side was more powerful Friday afternoon, and the SP climbed above $9.50... $10 is a first level resistance point, but once it is achieved, we can expect the SP to run towards $11.80... Support would be around $8.80 but considering the earnings was moved 2 weeks earlier (which may be a good sign),...
1. Jefferies upgraded the stock to buy from neutral expecting a 100% upside to the stock. Citing the ‘positive momentum and pipeline execution’ and rising investor attention, the analyst Michael Yee ups the price target to $30 from $15, nearly double its previous close. Prothena’s pipeline has significantly expanded and improved. The company’s early-stage...
Artelo Biosciences surged 92% on buy initiation from Ladenburg Shares of $ARTL Artelo Biosciences surged on friday after Ladenburg analyst Michael Higgins initiated the company with a buy rating. They give the biopharma a $7 price target. It also represents a potential 329% upside over the stock’s closing price on Thursday. Ladenburg analyst cites Artelo's...
"Assertio is a pharmaceutical company that sells prescription products in 3 areas: neurology, hospital, and pain and inflammation. The company is currently undergoing major restructuring and has recently merged with Zyla Life Sciences. They have 7 FDA approved products in the marketplace. Assertio currently has a market cap of only $150 million and has raised $50...
Buy this and send me some honey. Otherwise I will stop publishing these ideas, nothing comes free.
Hyping on twitter: Traders Citing Monday Filing Mentioning Proposed Merger of Co With StemoniX Q1 merger play 6.5m float. Three different 13G's filed in the last few days two 10% and one 5% www.marketscreener.com
Why $ANCN Anchiano Therapeutics Is Surging Today? Thanks to some news in December in the biopharma space, $ANCN stock is racing higher. So what was that news? And what else do you need to know? $ANCN Anchiano Therapeutics is captivating investors thanks to its Definitive Merger Agreement with Chemomab news in december. The proposed merger will create a public...
Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology Provides Expanded Protection to Seminal Patents Related to DNAbilize The new patent builds on earlier patents granted that protect the platform technology for DNAbilize®, the Company’s novel RNAi nanoparticle drugs. finance.yahoo.com
$KALV KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks – Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) – – KVD900 Generally Safe and...
Don't sleep on this one! **Not financial advice, do your own research!**
Symmetrical Triangle breakout. Bullish MACD cross. Likely gap up tomorrow after major news today: Empower Partners with Rexall(R) To Launch Integrated Healthcare Centres Partnership Accelerates Empower's Strategy To Execute National Healthcare Centre Expansion By Bringing Accessible and Progressive Primary Care and Para-Medical Care to Millions of...
Zomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million. today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less...
FDA decision on bladder cancer treatment Vicinium on Feb 16th, 2021. If approved, it's looking like SESN has a shot at breaking the $3.00 mark. And of course, Massachusetts-based stocks always get a thumbs up from me dawg 👍
Hyping on twitter: Added New position $OPGN primarily for the top catalyst FDA decision Acuitas AMR Gene Panel. In addition, pipeline includes Broad pathogen and Antimicrobial Resistance Marker coverage. 53 M market cap. Eyeing $3.3 breakout target towards $4 plus. Should spike on FDA decision. twitter.com
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of...
Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market. today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 3,000,000 shares of its common stock at a purchase price of $7.65 per share in a registered direct offering. The...